Jun 30, 2026 04:02PM
Jun 30, 2026 04:02PM
Jun 3, 2026 09:02AM
May 12, 2026 05:47AM
May 11, 2026 04:03PM
May 11, 2026 04:01PM
Apr 30, 2026 08:00AM Halozyme names Darren Snellgrove as chief financial officer
Apr 30, 2026 08:00AM
Apr 29, 2026 06:59AM
Mar 12, 2026 08:30AM
Mar 12, 2026 08:30AM
Feb 19, 2026 10:25AM
Feb 17, 2026 04:06PM
Feb 17, 2026 04:01PM HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Jan 28, 2026 06:30AM
Dec 8, 2025 04:05PM
Dec 8, 2025 04:05PM
Nov 18, 2025 08:50AM
Nov 18, 2025 08:50AM
Nov 6, 2025 11:37PM
Nov 6, 2025 11:37PM Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Nov 5, 2025 04:05PM
Nov 5, 2025 04:05PM
Nov 4, 2025 05:03AM
Nov 3, 2025 04:02PM
Nov 3, 2025 04:01PM
Oct 1, 2025 07:01AM
Oct 1, 2025 07:00AM Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
Sep 24, 2025 08:20AM
Aug 6, 2025 04:08AM
Aug 5, 2025 04:05PM
Aug 5, 2025 04:01PM
Jun 30, 2025 04:07PM
Jun 30, 2025 04:05PM
May 7, 2025 10:47AM Benchmark Reiterates Hold Rating on Halozyme Therapeutics (HALO)
May 6, 2025 04:17PM
May 6, 2025 04:01PM
Apr 21, 2025 06:41AM
Feb 19, 2025 06:56AM
Feb 19, 2025 04:37AM
Feb 18, 2025 04:03PM
Feb 18, 2025 04:01PM HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
Jan 8, 2025 07:00AM
Nov 18, 2024 07:03AM
Nov 18, 2024 07:00AM
Nov 14, 2024 04:16PM
Nov 14, 2024 04:15PM
Nov 4, 2024 08:43AM
Nov 4, 2024 06:46AM Halozyme Therapeutics (HALO) PT Raised to $68 at H.C. Wainwright
Oct 31, 2024 04:03PM

1,203,405 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All